Inhibrx Net Income 2020-2022 | INBX

Inhibrx net income from 2020 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Inhibrx Annual Net Income
(Millions of US $)
2021 $-82
2020 $-76
2019 $-51
Inhibrx Quarterly Net Income
(Millions of US $)
2022-03-31 $-31
2021-12-31 $-21
2021-09-30 $-21
2021-06-30 $-21
2021-03-31 $-19
2020-12-31 $-18
2020-09-30 $-20
2020-06-30 $-18
2020-03-31 $-20
2019-12-31
2019-09-30 $-20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.458B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Emergent Biosolutions (EBS) United States $1.646B 7.05
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00